A phase II study of Zanubrutinib in combination with rituximab in patients with relapsed/refractory aggressive and indolent B-cell lymphoma

Click to increase image sizeClick to decrease image size

Acknowledgments

The authors thank the patients who participated in the study, their supporters, the investigators, and the clinical research staff from the study centers. Medical editing assistance was funded by BeiGene and provided by Twist Medical LLC.

Disclosure statement

Meng Ji, Lu Zhang, Haiyi Guo, Jane Huang, Lina Fu and Jinhua Zhong are employees of and own stock in BeiGene. All other authors declare no conflict of interests.

Data availability statement

On request, and subject to certain criteria, conditions, and exceptions, BeiGene will provide access to individual de-identified participant data from BeiGene-sponsored global interventional clinical studies conducted for medicines (1) for indications that have been approved or (2) in programs that have been terminated. Data requests may be submitted to [email protected].

Additional information

Funding

This study was supported by research funding from BeiGene (Beijing) Co., Ltd.